William D.  Baird, III net worth and biography

William Baird, III Biography and Net Worth

CFO of 2seventy bio
William “Chip” Baird has served as a member of our board of directors since June 2018. He joined bluebird bio, Inc. as Chief Financial Officer in February 2019 and previously served as Chief Financial Officer of Amicus Therapeutics, Inc., a pharmaceutical company, from April 2012 to December 2018. Mr. Baird holds an M.B.A. in finance from The Wharton School of the University of Pennsylvania and a B.S.F.S. in international affairs from the Edmund A. Walsh School of Foreign Service of Georgetown University.

What is William D. Baird, III's net worth?

The estimated net worth of William D. Baird, III is at least $5.55 million as of March 17th, 2025. Mr. Baird, III owns 1,121,034 shares of 2seventy bio stock worth more than $5,549,118 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Baird, III may own. Learn More about William D. Baird, III's net worth.

How do I contact William D. Baird, III?

The corporate mailing address for Mr. Baird, III and other 2seventy bio executives is , , . 2seventy bio can also be reached via phone at 339-499-9300 and via email at investor@2seventybio.com. Learn More on William D. Baird, III's contact information.

Has William D. Baird, III been buying or selling shares of 2seventy bio?

During the past quarter, William D. Baird, III has sold $25,205.40 in 2seventy bio stock. Most recently, William D. Baird III sold 5,092 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $4.95, for a transaction totalling $25,205.40. Following the completion of the sale, the chief executive officer now directly owns 1,121,034 shares of the company's stock, valued at $5,549,118.30. Learn More on William D. Baird, III's trading history.

Who are 2seventy bio's active insiders?

2seventy bio's insider roster includes William Baird, III (CFO), Philip Gregory (Insider), Nicola Heffron (COO), and Nick Leschly (CEO). Learn More on 2seventy bio's active insiders.

Are insiders buying or selling shares of 2seventy bio?

During the last twelve months, insiders at the sold shares 11 times. They sold a total of 5,167,940 shares worth more than $25,462,068.53. The most recent insider tranaction occured on March, 17th when COO Jessica Snow sold 2,298 shares worth more than $11,375.10. Insiders at 2seventy bio own 7.2% of the company. Learn More about insider trades at 2seventy bio.

Information on this page was last updated on 3/17/2025.

William D. Baird, III Insider Trading History at 2seventy bio

See Full Table

William D. Baird, III Buying and Selling Activity at 2seventy bio

This chart shows William D Baird III's buying and selling at 2seventy bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$25ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k-$50k$0$50k$100kTotal Insider BuyingTotal Insider Selling

2seventy bio Company Overview

2seventy bio logo
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.95
Low: $4.95
High: $4.96

50 Day Range

MA: $3.24
Low: $2.30
High: $4.96

2 Week Range

Now: $4.95
Low: $2.29
High: $5.99

Volume

445,240 shs

Average Volume

608,345 shs

Market Capitalization

$255.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73